deltatrials
Completed NCT02094508

Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda

Impact of Trimethoprim-sulfamethoxazole Prophylaxis on Malaria Infection and Immunity in Children in Uganda

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Malaria
Updated 7 times since 2017 Last updated: Apr 4, 2018 Started: Mar 7, 2014 Primary completion: Dec 28, 2015 Completion: Dec 14, 2016

A observational or N/A phase clinical study on Malaria, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 7 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed

  2. Jul 2024 — Sep 2024 [monthly]

    Completed

  3. Jan 2021 — Jul 2024 [monthly]

    Completed

  4. Jun 2018 — Jan 2021 [monthly]

    Completed

  5. May 2018 — Jun 2018 [monthly]

    Completed

▶ Show 2 earlier versions

  1. Apr 2018 — May 2018 [monthly]

    Completed

    Phase: NA → None

  2. Jan 2017 — Apr 2018 [monthly]

    Completed NA

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Kalisizo, Uganda